Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

References

• Martorano LM, Winkelmann RR, Cebulla CM, Abdel-Rahman MH, Campbell SM. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. Int J Dermatol 2014; 53:657-63; PMID:24697775; http://dx.doi.org/10.1111/ijd.12386
   PubMed Web of Science ®Google Scholar
• Papadopoulos S, Benter T, Anastassiou G, Pape M, Gerhard S, Bornfeld N, Ludwig W-D, Dörken B. Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. Int J Cancer 2002; 99:193-200; PMID:11979433; http://dx.doi.org/10.1002/ijc.10297
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21; PMID:23945592; http://dx.doi.org/10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012; 25:171-81; PMID:22268848; http://dx.doi.org/10.1111/j.1755-148X.2012.00979.x
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43:D805-11; PMID:25355519; http://dx.doi.org/10.1093/nar/gku1075
   PubMed Web of Science ®Google Scholar
• Luscan A, Just PA, Briand A, des Roziers CB, Goussard P, Nitschké P, Vidaud M, Avril MF, Terris B, Pasmant E. Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. Br J Ophthalmol 2015; 99:437-9; PMID:25361747; http://dx.doi.org/10.1136/bjophthalmol-2014-305371
   PubMed Web of Science ®Google Scholar
• Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol Chic Ill 1960 2005; 123:1639 -43; PMID: 16344433; http://dx.doi.org/10.1001/archopht.123.12.1639
   Google Scholar
• Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107-8; PMID:8540843; http://dx.doi.org/10.1001/archopht.1996.01100130103030
   PubMedGoogle Scholar
• Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568-72; PMID:9856657; http://dx.doi.org/10.1097/00000421-199812000-00008
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014; 311:2397-405; PMID:24938562; http://dx.doi.org/10.1001/jama.2014.6096
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Kelderman S, van der Kooij MK, van den Eertwegh AJM, Soetekouw PMMB, Jansen RLH, van den Brom RRH, Hospers GAP, Haanen JBAG, Kapiteijn E, Blank CU. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol 2013; 52:1786-8; PMID:23607756; http://dx.doi.org/10.3109/0284186X.2013.786839
   PubMed Web of Science ®Google Scholar
• Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, Rosa FD, Vecchio MD, Guardo LD, Queirolo P et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911-5; PMID:24067719; http://dx.doi.org/10.1093/annonc/mdt376
   PubMed Web of Science ®Google Scholar
• Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E et al. Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE 2015; 10:e0118564; PMID:25761109; http://dx.doi.org/10.1371/journal.pone.0118564
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N et al. Mutations in GNA11 in Uveal Melanoma. N Engl J Med 2010; 363:2191-9; PMID:21083380; http://dx.doi.org/10.1056/NEJMoa1000584
   PubMed Web of Science ®Google Scholar
• Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. Br J Ophthalmol 2012; 96:451-8; PMID:22190731; http://dx.doi.org/10.1136/bjophthalmol-2011-300432
   PubMed Web of Science ®Google Scholar
• De Cruz POL, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65:112-5; PMID:2293857; http://dx.doi.org/10.1002/1097-0142(19900101)65:1%3c112::AID-CNCR2820650123%3e3.0.CO;2-X
   PubMed Web of Science ®Google Scholar
• Kottschade LA, McWilliams RR, Markovic S, Block MS, Villasboas Bisneto J, Pham AQ, Dronca RS. The use of pembrolizumab for the treatment of metastatic uveal melanoma. ASCO Meet Abstr 2015; 33:9010
   Google Scholar
• Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 2009; 45:228 -47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   Google Scholar
• Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 2011; 11:876 -8; PMID: 21241810; http://dx.doi.org/10.1016/j.intimp.2010.12.024
   Google Scholar
• Agarwala SS, Eggermont AMM, O'Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014; 120:781-9; PMID:24301420; http://dx.doi.org/10.1002/cncr.28480
   PubMed Web of Science ®Google Scholar
• den Brok MHMGM, Sutmuller RPM, Nierkens S, Bennink EJ, Frielink C, Toonen LWJ, Boerman OC, Figdor CG, Ruers TJM, Adema GJ. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006; 95:896; PMID:16953240; http://dx.doi.org/10.1038/sj.bjc.6603341
   PubMed Web of Science ®Google Scholar
• Haen SP, Pereira PL, Salih HR, Rammensee H-G, Gouttefangeas C. More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer. Clin Dev Immunol; vol. 2011, Article ID 160250, 19 pages, 2011; PMID: 22242035; http://dx.doi.org/10.1155/2011/160250
   Google Scholar